Intrapulmonary Cellular-Level Distribution of Inhaled Nanoparticles with Defined Functional Groups and Its Correlations with Protein Corona and Inflammatory Response
Source abstract
Abstract
Concerns over the health risks associated with airborne exposure to ultrafine particles [PM0.1, or nanoparticles (NPs)] call for a comprehensive understanding in the interactions of inhaled NPs along their respiratory journey. We prepare a collection of polyethylene glycol-coated gold nanoparticles that bear defined functional groups commonly identified in atmospheric particulates (Au@PEG-X NPs, where X = OCH3, COOH, NH2, OH, or C12H25). Regardless of the functional group, these ∼50 nm NPs remain colloidally stable following aerosolization and incubation in bronchoalveolar lavage fluid (BALF), without pronouncedly crossing the air–blood barrier. The type of BALF proteins adhered onto the NPs is similar, but the composition of protein corona depends on functional group. By subjecting Balb/c mice to inhalation of Au@PEG-X NPs for 6 h, we demonstrate that the intrapulmonary distribution of NPs among the various types of cells (both found in BALF and isolated from the lavaged lung) and the acute inflammatory responses induced by inhalation are sensitive to the functional group of NPs and postinhalation period (0, 24, or 48 h). By evaluating the pairwise correlations between the three variables of “lung–nano” interactions (protein corona, intrapulmonary cellular-level distribution, and inflammatory response), we reveal strong statistical correlations between the (1) fractions of albumin or carbonyl reductase bound to NPs, (2) associations of inhaled NPs to neutrophils in BALF or macrophages in the lavaged lung, and (3) level of total protein in BALF. Our results provide insights into the effect of functional group on lung–nano interactions and health risks associated with inhalation of PM0.1.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Nanoparticles: synthesis and applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Hong Kong Baptist University, Kowloon, Hong Kong
Funding
Health and Medical Research Fund · Research Grants Council, University Grants Committee · Innovation and Technology Fund · Croucher Foundation · Chow Yuk Ho Technology Centre for Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong
References (100+)
Show source-provided references
1. 10.1073/pnas.100646110810.1073/pnas.1006461108 ↗
2. 10.1073/pnas.160221211310.1073/pnas.1602212113 ↗
3. 10.1089/jam.2005.18.110.1089/jam.2005.18.1 ↗
4. 10.1007/s00408-004-2511-610.1007/s00408-004-2511-6 ↗
5. 10.1002/adfm.20170195610.1002/adfm.201701956 ↗
6. 10.1021/acsnano.6b0746110.1021/acsnano.6b07461 ↗
7. 10.1186/1743-8977-11-1810.1186/1743-8977-11-18 ↗
8. 10.1186/s12989-014-0049-110.1186/s12989-014-0049-1 ↗
9. 10.1089/jir.2008.002710.1089/jir.2008.0027 ↗
10. 10.1186/s12951-018-0436-010.1186/s12951-018-0436-0 ↗
11. 10.1080/0895837060074828110.1080/08958370600748281 ↗
12. 10.1080/0895837090294251710.1080/08958370902942517 ↗
13. 10.1038/nnano.2009.30510.1038/nnano.2009.305 ↗
14. 10.1073/pnas.181813411610.1073/pnas.1818134116 ↗
15. 10.2147/IJN.S12930010.2147/IJN.S129300 ↗
16. 10.1021/nn404481f10.1021/nn404481f ↗
17. 10.1016/j.jaci.2017.08.04910.1016/j.jaci.2017.08.049 ↗
18. 10.1021/ja208433810.1021/ja2084338 ↗
19. 10.1021/es404810z10.1021/es404810z ↗
20. 10.1007/s00204-014-1292-910.1007/s00204-014-1292-9 ↗
21. 10.1186/1743-8977-7-3910.1186/1743-8977-7-39 ↗
22. 10.1080/1743539080239829110.1080/17435390802398291 ↗
23. 10.1021/acsami.8b1792810.1021/acsami.8b17928 ↗
24. 10.1021/mp900107v10.1021/mp900107v ↗
25. 10.1038/nbt.169610.1038/nbt.1696 ↗
26. 10.1007/BF0005382310.1007/BF00053823 ↗
27. 10.1021/acs.accounts.9b0010310.1021/acs.accounts.9b00103 ↗
28. 10.4209/aaqr.2016.05.018310.4209/aaqr.2016.05.0183 ↗
29. 10.1016/j.atmosenv.2019.01.02310.1016/j.atmosenv.2019.01.023 ↗
30. 10.1016/S1352-2310(03)00461-810.1016/S1352-2310(03)00461-8 ↗
31. 10.1021/es803189n10.1021/es803189n ↗
32. 10.1021/acsnano.7b0204410.1021/acsnano.7b02044 ↗
33. 10.1021/es702809a10.1021/es702809a ↗
34. 10.1039/C8NR04927K10.1039/C8NR04927K ↗
35. 10.1016/0095-8522(58)90055-210.1016/0095-8522(58)90055-2 ↗
36. 10.1289/ehp.946910.1289/ehp.9469 ↗
37. 10.1038/jes.2014.210.1038/jes.2014.2 ↗
38. 10.1021/acsnano.9b0277410.1021/acsnano.9b02774 ↗
39. 10.1039/c0cp02967j10.1039/c0cp02967j ↗
40. 10.1186/1743-8977-9-4110.1186/1743-8977-9-41 ↗
41. U.S. Food and Drug Administration. Bacterial Endotoxins/Pyrogens. November, 2014, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/bacterial-endotoxinspyrogens. (Last accessed Nov 8, 2019).
42. 10.1038/nprot.2015.04710.1038/nprot.2015.047 ↗
43. 10.1038/nnano.2015.33010.1038/nnano.2015.330 ↗
44. 10.1021/acsnano.5b0421510.1021/acsnano.5b04215 ↗
45. 10.1186/s12989-017-0223-310.1186/s12989-017-0223-3 ↗
46. 10.1165/ajrcmb.19.2.14010.1165/ajrcmb.19.2.140 ↗
47. 10.1096/fj.00-0318rev10.1096/fj.00-0318rev ↗
48. 10.1016/j.jconrel.2015.09.00410.1016/j.jconrel.2015.09.004 ↗
49. 10.3109/17435390.2012.68988010.3109/17435390.2012.689880 ↗
50. 10.1074/jbc.272.4.221810.1074/jbc.272.4.2218 ↗
51. 10.1177/38.2.168889710.1177/38.2.1688897 ↗
52. 10.1016/j.toxlet.2012.04.00610.1016/j.toxlet.2012.04.006 ↗
53. 10.1038/s41467-019-12279-210.1038/s41467-019-12279-2 ↗
54. 10.1165/rcmb.2007-0138OC10.1165/rcmb.2007-0138OC ↗
55. 10.1007/BF0021602710.1007/BF00216027 ↗
56. 10.1038/labinvest.2010.18710.1038/labinvest.2010.187 ↗
57. 10.5339/gcsp.2015.210.5339/gcsp.2015.2 ↗
58. 10.1038/srep2626910.1038/srep26269 ↗
59. 10.1021/acsnano.6b0624510.1021/acsnano.6b06245 ↗
60. 10.1038/labinvest.378022010.1038/labinvest.3780220 ↗
61. 10.1155/2017/671027810.1155/2017/6710278 ↗
62. 10.7150/thno.1806910.7150/thno.18069 ↗
63. 10.1128/IAI.00454-0910.1128/IAI.00454-09 ↗
64. 10.1189/jlb.031113410.1189/jlb.0311134 ↗
65. 10.1016/j.nano.2015.11.00210.1016/j.nano.2015.11.002 ↗
66. Franke-Ullmann G. · J. Immunol. · 1996 · 157 · 309710.4049/jimmunol.157.7.3097 ↗
67. 10.4049/jimmunol.179.6.348810.4049/jimmunol.179.6.3488 ↗
68. 10.1007/BF0023201010.1007/BF00232010 ↗
69. 10.1021/acsnano.7b0699510.1021/acsnano.7b06995 ↗
70. 10.1021/acsnano.8b0014110.1021/acsnano.8b00141 ↗
71. 10.5194/acp-17-11423-201710.5194/acp-17-11423-2017 ↗
72. 10.1186/1743-8977-6-210.1186/1743-8977-6-2 ↗
73. 10.1007/s11051-015-3249-110.1007/s11051-015-3249-1 ↗
74. 10.1074/jbc.M111.25188410.1074/jbc.M111.251884 ↗
75. 10.1111/j.1440-1681.2011.05498.x10.1111/j.1440-1681.2011.05498.x ↗
76. 10.3109/17435390.2015.102288710.3109/17435390.2015.1022887 ↗
77. 10.1183/09031936.96.0908173610.1183/09031936.96.09081736 ↗
78. 10.3109/17435390.2011.63581410.3109/17435390.2011.635814 ↗
79. 10.1111/j.1538-7836.2010.03751.x10.1111/j.1538-7836.2010.03751.x ↗
80. 10.1165/rcmb.2004-0309OC10.1165/rcmb.2004-0309OC ↗
81. 10.1046/j.1524-475x.2001.00028.x10.1046/j.1524-475x.2001.00028.x ↗
82. 10.2147/IJN.S3611110.2147/IJN.S36111 ↗
83. 10.1021/ja210890510.1021/ja2108905 ↗
84. 10.1186/1743-8977-7-3710.1186/1743-8977-7-37 ↗
85. 10.1093/toxsci/kfm01810.1093/toxsci/kfm018 ↗
86. 10.1152/ajplung.1998.274.6.L95810.1152/ajplung.1998.274.6.L958 ↗
87. 10.1038/nnano.2014.1710.1038/nnano.2014.17 ↗
88. 10.1242/dmm.01911710.1242/dmm.019117 ↗
89. 10.1152/ajplung.00045.200910.1152/ajplung.00045.2009 ↗
90. 10.1371/journal.pone.004077510.1371/journal.pone.0040775 ↗
91. 10.1152/ajplung.1996.270.4.L67710.1152/ajplung.1996.270.4.L677 ↗
92. 10.1016/S0092-8674(03)00758-X10.1016/S0092-8674(03)00758-X ↗
93. 10.1152/ajplung.1992.262.5.L60010.1152/ajplung.1992.262.5.L600 ↗
94. 10.1165/rcmb.2014-0255OC10.1165/rcmb.2014-0255OC ↗
95. 10.1038/physci241020a010.1038/physci241020a0 ↗
96. 10.1021/am501599f10.1021/am501599f ↗
97. 10.1021/ac070208410.1021/ac0702084 ↗
98. 10.1002/adhm.20120008410.1002/adhm.201200084 ↗
99. 10.1021/acs.langmuir.8b0257210.1021/acs.langmuir.8b02572 ↗
100. 10.1021/acsnano.9b0159110.1021/acsnano.9b01591 ↗